comscoreTargeted Therapy

Targeted Therapy

188 Research news
 
 
Article
Kadcyla Approved to Treat Early-Stage HER2-Positive Breast Cancer

On May 3, 2019, the FDA approved Kadcyla to treat early-stage HER2-positive breast cancer after surgery if there were cancer cells found during surgery after neoadjuvant chemotherapy with a taxane and Herceptin.

 
Article
Kisqali Plus Faslodex Improves Overall Survival in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy.

 
Article
CDK4/6 Inhibitor Plus Aromatase Inhibitor Helps Treat Breast Cancer, No Matter a Woman's Age

An analysis of three studies on different CDK4/6 inhibitors in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer found the treatment combination was effective in both younger and older women.

 
Article
Subcutaneous Herceptin and Perjeta Combined With Chemo Before Breast Cancer Surgery Offers Same Benefits as IV Versions

A fixed-dose combination of Herceptin and Perjeta given as an injection in the thigh along with chemotherapy before surgery seems to offer the same benefits as IV infusions of the two medicines for people diagnosed with early-stage HER2-positive breast cancer.

Dec 20, 2019 | Diagnosis and Targeted Therapy
 
Article
People Receiving Cancer Treatment Develop ‘Adequate’ Immune Response to Pfizer COVID-19 Vaccine

Nearly all the people in a clinical trial who were receiving systemic intravenous cancer treatment had an adequate immune response to the Pfizer-BioNTech COVID-19 vaccine.

 
Article
Herceptin Plus Tykerb After Surgery No Better Than Herceptin Alone for Early-Stage, HER2-Positive Disease

Women diagnosed with early-stage, HER2-positive breast cancer treated with both Herceptin and Tykerb after surgery had the same disease-free survival as women treated with only Herceptin after surgery.

Nov 28, 2015 | Diagnosis and Targeted Therapy
 
Article
FDA Warns About Rare but Severe Lung Inflammation Linked to Breast Cancer Drugs Ibrance, Kisqali, and Verzenio

On Sept. 13, 2019, the FDA released a statement warning about a link between rare but severe lung inflammation and the three CDK4/6 inhibitors used to treat advanced-stage hormone-receptor-positive, HER2-negative breast cancer.

Sep 17, 2019 | Diagnosis and Targeted Therapy
 
Article
Heart Medicines Seem to Reduce Risk of Serious Cardiac Damage in Women Taking Herceptin

A small study suggests that heart medicines, such as beta blockers or ACE inhibitors, taken along with Herceptin can reduce the risk of serious heart damage in women diagnosed with early-stage, HER2-positive breast cancer.

 
Article
Adding Afinitor to Faslodex Helps Treat Metastatic Disease That's AI-Resistant

Adding Afinitor to Faslodex offers benefits when treating metastatic, hormone-receptor-positive, HER2-negative breast cancer that has become resistant to aromatase inhibitors.

 
Article
Verzenio Plus Faslodex Improves Overall Survival by 9 Months in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Latest results from MONARCH 2 study show adding Verzenio to Faslodex improves overall survival by 9 months for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.

 
Article
FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer

On April 22, 2020, the FDA granted accelerated approval to Trodelvy to treat adults diagnosed with metastatic triple-negative breast cancer who have received at least two previous treatments for metastatic disease.

Apr 22, 2020 | Diagnosis and Targeted Therapy
 
Article
Experimental Alpelisib May Help Treat Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer With Specific Mutation

Experimental alpelisib combined with Faslodex improved progression-free survival more than Faslodex alone in people diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

 
Article
Nerlynx Approved by FDA to Treat Early-Stage, HER2-Positive Breast Cancer

Nerlynx was approved by the FDA on July 17, 2017 to treat early-stage, HER2-positive breast cancer for an extended period after surgery in people who have previously been treated with Herceptin.

Jul 18, 2017 | Diagnosis and Targeted Therapy
 
Article
Kisqali Can Help Treat Younger Women With Metastatic Hormone-Receptor-Positive Disease

Kisqali along with either an aromatase inhibitor or tamoxifen and medicine to suppress ovarian function offers better progression-free survival than just hormonal therapy and ovarian suppression in premenopausal women with advanced-stage, hormone-receptor-positive, HER2-negative disease.

 
Article
Avastin Doesn't Affect Overall Survival

Avastin combined with Taxol lengthens the time until advanced breast cancer progresses, but doesn't improve overall survival.

 
Article
FDA Recommends Removing Avastin's Breast Cancer Indication

The FDA has recommended removing the breast cancer indication from Avastin because the medicine has not been shown to be safe and effective for that use.

Dec 16, 2010 | Diagnosis and Targeted Therapy
 
Article
If Cancer Stops Responding to Herceptin, It May Have Switched From HER2-Positive to HER2-Negative

A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.

 
Article
Nexavar May Make Metastatic Cancers Start Responding to Hormonal Therapy Again

A preliminary study suggests that a targeted therapy may be able to make hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again.

 
Article
New Chemo Meds Improve Survival for Women With Advanced-Stage Disease

Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.

 
Article
Avastin Doesn't Improve Survival in Metastatic Breast Cancer

The FDA is considering whether to continue the approval for using Avastin with Taxol to treat metastatic breast cancer, as well as whether to approve it in combination with other medicines.

 
Article
FDA Turns Down Accelerated Approval Request for T-DM1

The FDA has decided to not consider accelerated approval for T-DM1 to treat HER2-positive, advanced-stage breast cancer based on research results available as of August 2010.

Aug 27, 2010 | Diagnosis and Targeted Therapy
 
Article
Herceptin Works Well in Older Women Diagnosed With HER2-Positive, Metastatic Disease

A small study suggests that older women diagnosed with HER2-positive, metastatic breast cancer can benefit from Herceptin treatment.

Oct 10, 2010 | Diagnosis and Targeted Therapy
 
Article
Avastin Added to Chemo Before Surgery Offers No Benefit

Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.

 
Article
Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease

Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.

Showing 24 of 188